1,094
Views
1
CrossRef citations to date
0
Altmetric
Research Paper

The NOP14 nucleolar protein suppresses the function and stemness of melanoma stem-like cells through Wnt/beta-catenin signaling inactivation

, , , , &
Pages 7648-7658 | Received 30 Dec 2021, Accepted 02 Mar 2022, Published online: 12 Mar 2022

References

  • Ko JS. The Immunology of Melanoma. Clin Lab Med. 2017;37(3):449–471.
  • Owens B. Melanoma. Nature. 2014;515(7527):S109–S109.
  • Corrie P, Hategan M, Fife K, et al. Management of melanoma. Br Med Bull. 2014;111(1):149–162.
  • Lee JA. Current evidence about the causes of malignant melanoma. Prog Clin Cancer. 1975;6:151–161.
  • Deschner B, Wayne JD. Follow-up of the melanoma patient. J Surg Oncol. 2018;12:25324.
  • Walcher L, Kistenmacher A-K, Suo H, et al. Cancer Stem Cells-Origins and Biomarkers: perspectives for Targeted Personalized Therapies. Front Immunol. 2020;11:1280.
  • Babaei G, Aziz SG-G, Jaghi NZZ. EMT, cancer stem cells and autophagy; The three main axes of metastasis. Biomed Pharmacother. 2021;133:110909.
  • Mansour H, Hassan G, Afify SM, et al. Metastasis Model of Cancer Stem Cell-Derived Tumors. Methods Protoc. 2020;3(3):60.
  • Chang JC. Cancer stem cells: role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine (Baltimore). 2016;95(1S):S20–s25.
  • Huang T, Song X, Xu D, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10(19):8721–8743.
  • Vermeulen L, de Sousa E Melo F, Richel DJ, et al. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012;13(2):e83–89.
  • Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65(20):9328–9337.
  • Perego M, Tortoreto M, Tragni G, et al. Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J Invest Dermatol. 2010;130(7):1877–1886.
  • Valcourt DM, Dang MN, Wang J, et al. Nanoparticles for manipulation of the developmental wnt, hedgehog, and notch signaling pathways in cancer. Ann Biomed Eng. 2020;48(7):1864–1884.
  • McGrath NA, Fu J, Gu SZ, et al. Targeting cancer stem cells in cholangiocarcinoma (Review). Int J Oncol. 2020;57(2):397–408.
  • Bugter JM, Fenderico N, Maurice MM. Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat Rev Cancer. 2021;21(1):5–21.
  • Li J, Fang R, Wang J, et al. NOP14 inhibits melanoma proliferation and metastasis by regulating Wnt/β-catenin signaling pathway. Braz J Med Biol Res. 2019;52(1):e7952.
  • Korn P, Kampmann A, Spalthoff S, et al. Suitability of CD133 as a Marker for Cancer Stem Cells in Melanoma. Asian Pac J Cancer Prev. 2021;22:1591–1597.
  • Rajendran V, Jain MV. In Vitro Tumorigenic Assay: colony Forming Assay for Cancer Stem Cells. Methods Mol Biol. 2018;1692:89–95.
  • Guo H, Xia B. Collapsin response mediator protein 4 isoforms (CRMP4a and CRMP4b) have opposite effects on cell proliferation, migration, and invasion in gastric cancer. BMC Cancer. 2016;16(1):565.
  • Han H, Zhan Z, Xu J, et al. TMEFF2 inhibits pancreatic cancer cells proliferation, migration, and invasion by suppressing phosphorylation of the MAPK signaling pathway. Onco Targets Ther. 2019;12:11371–11382.
  • Xu Q, Liu Z, Zhu ZQ, et al. Knockdown of growth factor receptor bound protein 7 suppresses angiogenesis by inhibiting the secretion of vascular endothelial growth factor A in ovarian cancer cells. Bioengineered. 2021;12(2):12179–12190.
  • Yao L, Zhao H, Tang H, et al. Blockade of β-catenin signaling attenuates toluene diisocyanate-induced experimental asthma. Allergy. 2017;72(4):579–589.
  • Liou GY. CD133 as a regulator of cancer metastasis through the cancer stem cells. Int J Biochem Cell Biol. 2019;106:1–7.
  • He Z, Guo X, Tian S, et al. MicroRNA-137 reduces stemness features of pancreatic cancer cells by targeting KLF12. J Exp Clin Cancer Res. 2019;38(1):126.
  • Markowska A, Sajdak S, Markowska J, et al. Angiogenesis and cancer stem cells: new perspectives on therapy of ovarian cancer. Eur J Med Chem. 2017;142:87–94.
  • Krishnapriya S, Sidhanth C, Manasa P, et al. Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary. Angiogenesis. 2019;22(3):441–455.
  • Nusse R, Clevers H. Wnt/β-Catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–999.
  • Yost C, Torres M, Miller JR, et al. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 1996;10(12):1443–1454.
  • Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234(6):8381–8395.